• Je něco špatně v tomto záznamu ?

Phosphodiesterase 1 regulation is a key mechanism in vascular aging

PK. Niño, M. Durik, AH. Danser, R. de Vries, UM. Musterd-Bhaggoe, ME. Meima, M. Kavousi, M. Ghanbari, JH. Hoeijmakers, CJ. O'Donnell, N. Franceschini, GM. Janssen, JG. De Mey, Y. Liu, CM. Shanahan, OH. Franco, A. Dehghan, AJ. Roks,

. 2015 ; 129 (12) : 1061-75. [pub] 20150625

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16000014

Reduced nitric oxide (NO)/cGMP signalling is observed in age-related vascular disease. We hypothesize that this disturbed signalling involves effects of genomic instability, a primary causal factor in aging, on vascular smooth muscle cells (VSMCs) and that the underlying mechanism plays a role in human age-related vascular disease. To test our hypothesis, we combined experiments in mice with genomic instability resulting from the defective nucleotide excision repair gene ERCC1 (Ercc1(d/-) mice), human VSMC cultures and population genome-wide association studies (GWAS). Aortic rings of Ercc1(d/-) mice showed 43% reduced responses to the soluble guanylate cyclase (sGC) stimulator sodium nitroprusside (SNP). Inhibition of phosphodiesterase (PDE) 1 and 5 normalized SNP-relaxing effects in Ercc1(d/-) to wild-type (WT) levels. PDE1C levels were increased in lung and aorta. cGMP hydrolysis by PDE in lungs was higher in Ercc1(d/-) mice. No differences in activity or levels of cGMP-dependent protein kinase 1 or sGC were observed in Ercc1(d/-) mice compared with WT. Senescent human VSMC showed elevated PDE1A and PDE1C and PDE5 mRNA levels (11.6-, 9- and 2.3-fold respectively), which associated with markers of cellular senescence. Conversely, PDE1 inhibition lowered expression of these markers. Human genetic studies revealed significant associations of PDE1A single nucleotide polymorphisms with diastolic blood pressure (DBP; β=0.28, P=2.47×10(-5)) and carotid intima-media thickness (cIMT; β=-0.0061, P=2.89×10(-5)). In summary, these results show that genomic instability and cellular senescence in VSMCs increase PDE1 expression. This might play a role in aging-related loss of vasodilator function, VSMC senescence, increased blood pressure and vascular hypertrophy.

Cardiovascular Division James Black Centre King's College London SE5 9NU U K

Department of Epidemiology Erasmus MC Rotterdam 3015 CN The Netherlands

Department of Epidemiology University of North Carolina Chapel Hill Chapel Hill NC 27599 7435 U S A

Department of Genetics Erasmus MC Rotterdam 3015 CN The Netherlands

Department of Internal Medicine Division of Endocrinology Erasmus MC Rotterdam 3015 CN The Netherlands

Department of Internal Medicine Division of Vascular Disease and Pharmacology Erasmus MC Rotterdam 3015 CN The Netherlands

Department of Internal Medicine Division of Vascular Disease and Pharmacology Erasmus MC Rotterdam 3015 CN The Netherlands Department of Epidemiology Erasmus MC Rotterdam 3015 CN The Netherlands

Department of Internal Medicine Division of Vascular Disease and Pharmacology Erasmus MC Rotterdam 3015 CN The Netherlands Institute of Molecular Genetics Academy of Sciences of the Czech Republic 142 20 Prague Czech Republic

Department of Pharmacology Maastricht University 6211 LK The Netherlands

Department of Pharmacology Maastricht University 6211 LK The Netherlands Department of Cardiovascular and Renal research Institute of Molecular Medicine University of Southern Denmark 5230 Odense Denmark

National Heart Lung and Blood Institute's Framingham Heart Study Framingham MA 01702 5827 U S A National Heart Lung and Blood Institute Bethesda MD 20892 U S A Cardiology Division Department of Medicine Massachusetts General Hospital Harvard Medical School Boston MA 02114 U S A

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16000014
003      
CZ-PrNML
005      
20160122125132.0
007      
ta
008      
160108s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1042/CS20140753 $2 doi
035    __
$a (PubMed)26464516
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Niño, Paula K Bautista $u Department of Internal Medicine, Division of Vascular Disease and Pharmacology, Erasmus MC Rotterdam, 3015 CN, The Netherlands Department of Epidemiology, Erasmus MC Rotterdam, 3015 CN, The Netherlands.
245    10
$a Phosphodiesterase 1 regulation is a key mechanism in vascular aging / $c PK. Niño, M. Durik, AH. Danser, R. de Vries, UM. Musterd-Bhaggoe, ME. Meima, M. Kavousi, M. Ghanbari, JH. Hoeijmakers, CJ. O'Donnell, N. Franceschini, GM. Janssen, JG. De Mey, Y. Liu, CM. Shanahan, OH. Franco, A. Dehghan, AJ. Roks,
520    9_
$a Reduced nitric oxide (NO)/cGMP signalling is observed in age-related vascular disease. We hypothesize that this disturbed signalling involves effects of genomic instability, a primary causal factor in aging, on vascular smooth muscle cells (VSMCs) and that the underlying mechanism plays a role in human age-related vascular disease. To test our hypothesis, we combined experiments in mice with genomic instability resulting from the defective nucleotide excision repair gene ERCC1 (Ercc1(d/-) mice), human VSMC cultures and population genome-wide association studies (GWAS). Aortic rings of Ercc1(d/-) mice showed 43% reduced responses to the soluble guanylate cyclase (sGC) stimulator sodium nitroprusside (SNP). Inhibition of phosphodiesterase (PDE) 1 and 5 normalized SNP-relaxing effects in Ercc1(d/-) to wild-type (WT) levels. PDE1C levels were increased in lung and aorta. cGMP hydrolysis by PDE in lungs was higher in Ercc1(d/-) mice. No differences in activity or levels of cGMP-dependent protein kinase 1 or sGC were observed in Ercc1(d/-) mice compared with WT. Senescent human VSMC showed elevated PDE1A and PDE1C and PDE5 mRNA levels (11.6-, 9- and 2.3-fold respectively), which associated with markers of cellular senescence. Conversely, PDE1 inhibition lowered expression of these markers. Human genetic studies revealed significant associations of PDE1A single nucleotide polymorphisms with diastolic blood pressure (DBP; β=0.28, P=2.47×10(-5)) and carotid intima-media thickness (cIMT; β=-0.0061, P=2.89×10(-5)). In summary, these results show that genomic instability and cellular senescence in VSMCs increase PDE1 expression. This might play a role in aging-related loss of vasodilator function, VSMC senescence, increased blood pressure and vascular hypertrophy.
650    _2
$a stárnutí $x genetika $x metabolismus $7 D000375
650    _2
$a zvířata $7 D000818
650    _2
$a krevní tlak $7 D001794
650    _2
$a arteriae carotides $x enzymologie $x patologie $7 D002339
650    _2
$a nemoci arterie carotis $x enzymologie $x genetika $x patologie $7 D002340
650    _2
$a intimomediální šíře tepenné stěny $7 D059168
650    _2
$a stárnutí buněk $7 D016922
650    _2
$a kultivované buňky $7 D002478
650    _2
$a guanosinmonofosfát cyklický $x metabolismus $7 D006152
650    _2
$a cyklické nukleotidfosfodiesterasy, typ 1 $x antagonisté a inhibitory $x genetika $x metabolismus $7 D054677
650    _2
$a cyklické nukleotidfosfodiesterasy, typ 5 $x genetika $x metabolismus $7 D054706
650    _2
$a DNA vazebné proteiny $x nedostatek $x genetika $7 D004268
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a endonukleasy $x nedostatek $x genetika $7 D004720
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a celogenomová asociační studie $7 D055106
650    _2
$a lidé $7 D006801
650    _2
$a hydrolýza $7 D006868
650    _2
$a hyperplazie $7 D006965
650    _2
$a hypertenze $x enzymologie $x genetika $x patofyziologie $7 D006973
650    _2
$a techniky in vitro $7 D066298
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a myši knockoutované $7 D018345
650    _2
$a svaly hladké cévní $x účinky léků $x enzymologie $7 D009131
650    _2
$a myocyty hladké svaloviny $x účinky léků $x enzymologie $7 D032389
650    _2
$a fenotyp $7 D010641
650    _2
$a inhibitory fosfodiesterasy 5 $x farmakologie $7 D058986
650    _2
$a jednonukleotidový polymorfismus $7 D020641
650    _2
$a systémy druhého messengeru $7 D015290
650    12
$a vazodilatace $x účinky léků $7 D014664
650    _2
$a vazodilatancia $x farmakologie $7 D014665
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Durik, Matej $u Department of Internal Medicine, Division of Vascular Disease and Pharmacology, Erasmus MC Rotterdam, 3015 CN, The Netherlands Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, 142 20 Prague, Czech Republic.
700    1_
$a Danser, A H Jan $u Department of Internal Medicine, Division of Vascular Disease and Pharmacology, Erasmus MC Rotterdam, 3015 CN, The Netherlands.
700    1_
$a de Vries, René $u Department of Internal Medicine, Division of Vascular Disease and Pharmacology, Erasmus MC Rotterdam, 3015 CN, The Netherlands.
700    1_
$a Musterd-Bhaggoe, Usha M $u Department of Internal Medicine, Division of Vascular Disease and Pharmacology, Erasmus MC Rotterdam, 3015 CN, The Netherlands.
700    1_
$a Meima, Marcel E $u Department of Internal Medicine, Division of Endocrinology, Erasmus MC Rotterdam, 3015 CN, The Netherlands.
700    1_
$a Kavousi, Maryam $u Department of Epidemiology, Erasmus MC Rotterdam, 3015 CN, The Netherlands.
700    1_
$a Ghanbari, Mohsen $u Department of Epidemiology, Erasmus MC Rotterdam, 3015 CN, The Netherlands.
700    1_
$a Hoeijmakers, Jan H $u Department of Genetics, Erasmus MC Rotterdam, 3015 CN, The Netherlands.
700    1_
$a O'Donnell, Christopher J $u National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA 01702-5827, U.S.A. National Heart, Lung, and Blood Institute, Bethesda, MD 20892, U.S.A. Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, U.S.A.
700    1_
$a Franceschini, Nora $u Department of Epidemiology, University of North Carolina Chapel Hill, Chapel Hill, NC 27599-7435, U.S.A.
700    1_
$a Janssen, Ger M J $u Department of Pharmacology, Maastricht University, 6211 LK, The Netherlands.
700    1_
$a De Mey, Jo G R $u Department of Pharmacology, Maastricht University, 6211 LK, The Netherlands Department of Cardiovascular and Renal research, Institute of Molecular Medicine, University of Southern Denmark, 5230 Odense, Denmark.
700    1_
$a Liu, Yiwen $u Cardiovascular Division, James Black Centre, King's College, London SE5 9NU, U.K.
700    1_
$a Shanahan, Catherine M $u Cardiovascular Division, James Black Centre, King's College, London SE5 9NU, U.K.
700    1_
$a Franco, Oscar H $u Department of Epidemiology, Erasmus MC Rotterdam, 3015 CN, The Netherlands.
700    1_
$a Dehghan, Abbas $u Department of Epidemiology, Erasmus MC Rotterdam, 3015 CN, The Netherlands.
700    1_
$a Roks, Anton J M $u Department of Internal Medicine, Division of Vascular Disease and Pharmacology, Erasmus MC Rotterdam, 3015 CN, The Netherlands a.roks@erasmusmc.nl.
773    0_
$w MED00009494 $t Clinical science (London, England 1979) $x 1470-8736 $g Roč. 129, č. 12 (2015), s. 1061-75
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26464516 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160108 $b ABA008
991    __
$a 20160122125252 $b ABA008
999    __
$a ok $b bmc $g 1102295 $s 924220
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 129 $c 12 $d 1061-75 $e 20150625 $i 1470-8736 $m Clinical science (1979) $n Clin Sci (Lond) $x MED00009494
LZP    __
$a Pubmed-20160108

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...